

LJMU Research Online

Kwon, H, Basran, J, Pathak, C, Hussain, M, Freeman, SL, Fielding, AJ, Bailey, AJ, Stefanou, N, Sparkes, HA, Tosha, T, Yamashita, K, Hirata, K, Murakami, H, Ueno, G, Ago, H, Tono, K, Yamamoto, M, Sawai, H, Shiro, Y, Sugimoto, H, Raven, E and Moody, PCE

XFEL Crystal Structures of Peroxidase Compound II.

http://researchonline.ljmu.ac.uk/id/eprint/14823/

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Kwon, H, Basran, J, Pathak, C, Hussain, M, Freeman, SL, Fielding, AJ, Bailey, AJ, Stefanou, N, Sparkes, HA, Tosha, T, Yamashita, K, Hirata, K, Murakami, H, Ueno, G, Ago, H, Tono, K, Yamamoto, M, Sawai, H, Shiro, Y, Sugimoto. H. Raven. E and Moodv. PCE (2021) XFEL Crystal Structures of

LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

http://researchonline.ljmu.ac.uk/

http://researchonline.ljmu.ac.uk/

XFEL Crystal Structures of Peroxidase Compound II

Hanna Kwon¹, Jaswir Basran², Chinar Pathak², Mahdi Hussain², Samuel L. Freeman¹, Alistair J. Fielding³, Anna J. Bailey¹, Natalia Stefanou,¹ Hazel A. Sparkes¹, Takehiko Tosha⁴, Keitaro Yamashita^{4,5}, Kunio Hirata⁴ Hironori Murakami⁶, Go Ueno⁴, Hideo Ago⁴, Kensuke Tono⁶, Masaki Yamamoto⁴, Hitomi Sawai⁷, Yoshitsugu Shiro⁷, Hiroshi Sugimoto⁴, Emma L. Raven^{1,*} and Peter C. E. Moody^{2,*}

¹ School of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK

² Department of Molecular and Cell Biology and Leicester Institute of Structural and Chemical Biology, University of Leicester, Lancaster Road, Leicester, LE1 7RH, UK

³ Centre for Natural Products Discovery, Pharmacy and Biomolecular Sciences, James Parsons Building, Byrom Street, Liverpool John Moores University, Liverpool, L3 3AF, UK

⁴ RIKEN SPring-8 Center, 1-1-1 Kouto, Sayo, Hyogo, 679-5148, Japan

⁵ Present address: MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB1 0QH, UK

⁶ Japanese Synchrotron Radiation Research Institute, 1-1-1 Kouto, Sayo, Hyogo, 679-5198, Japan

⁷ Graduate School of Life Science, University of Hyogo, 3-2-1 Kouto, Kamigori-cho, Ako-gun, Hyogo, 678-1297, Japan

^{*} To whom correspondence should be addressed.

ABSTRACT

Oxygen activation in all heme enzymes requires the formation of high oxidation states of iron, usually referred to as ferryl heme. There are two known intermediates: Compound I and Compound II. The nature of the ferryl heme – and whether it is an Fe^{IV}=O or Fe^{IV}-OH species – is important for controlling reactivity across groups of heme enzymes. The most recent evidence for Compound I indicates that the ferryl heme is an unprotonated Fe^{IV}=O species. For Compound II, the nature of the ferryl heme is not unambiguously established. Here, we report 1.06 Å and 1.50 Å crystal structures for Compound II intermediates in cytochrome *c* peroxidase (C*c*P) and ascorbate peroxidase (APX), collected using the X-ray free electron laser at SACLA. The structures reveal differences between the two peroxidases. The iron-oxygen bond length in C*c*P (1.76 Å) is notably shorter than in APX (1.87 Å). The results indicate that the ferryl species is finely tuned across Compound I and Compound II species in closely related peroxidase enzymes. We propose that this fine-tuning is linked to the functional need for proton delivery to the heme.

INTRODUCTION

A large number of heme enzymes use ferryl heme during catalysis. Ferryl heme refers broadly to a highly oxidized form of the heme in which the iron is in an oxidation state that is either one equivalent (Fe^{IV}, known as Compound II) or two equivalents (formally Fe^V, known as Compound I) above the resting oxidation state (Fe^{III}). The second oxidizing equivalent in Compound I resides on the porphyrin ring or, in some cases, on a protein radical^[1].

These Compound I and Compound II species were identified in the late 1930s^[2] and were later given their names^[3]. Because these intermediates are used in such a wide range of catalytic enzymes, they continue to attract attention these many years later^[4]. The chemical nature of the ferryl species has therefore been a matter of intense interest. The discussion has often focussed on whether the ferryl species is best formulated as an unprotonated Fe^{IV}=O or a protonated Fe^{IV}-OH species. This matters because the protonation state controls the reactivity. The majority of the early spectroscopy on these intermediates was carried out on one of the more experimentally amenable peroxidases (usually horseradish peroxidase or

cytochrome *c* peroxidase), or on myoglobin, each of which contain a histidine as proximal ligand. Most, but not all, of this information favoured an unprotonated $Fe^{IV}=O$ species for Compound I^[5]. But the difficulty of the experiments on such unstable species, coupled with the problems associated with generating them in quantitative yields and sometimes in high concentrations, meant that the literature was inconclusive.

From about 2000 onwards, the field moved away from spectroscopy and X-ray crystallographic work became feasible instead. Since protons are not normally visible at the resolutions typically observed for protein crystal structures, the question instead became focussed on the iron-oxygen bond length which was taken as an indirect reporter of bond order (single or double). Protonation state ($Fe^{IV}=O$ or $Fe^{IV}-OH$) is thus inferred from the bond length measured in the structure. But the picture did not clarify when X-ray structures of ferryl species emerged, because the structures revealed bond lengths that were longer than would be expected for a pure $Fe^{IV}=O$ species and were thus out-of-line with most of the earlier spectroscopy. Photoreduction of metal ions in the synchrotron beam is now known to be an issue that affects oxidation states of metal ions in metalloprotein structures^[6], including those for the early Compound I crystal structures (reviewed in ^[1b, 7]). X-ray free electron lasers (XFEL) avoid this problem because it becomes possible to collect the diffraction data within femtosecond timescales, which allows data collection before the X-ray induced photoreduction/radiation damage take place^[8].

In this work, we present XFEL structures of Compound II in two different peroxidases – cytochrome c peroxidase and ascorbate peroxidase. The data indicate differences in the nature of the ferryl species between the Compound II intermediates in the two enzyme intermediates. The functional implications of this finding, in terms of proton delivery to the heme, are discussed.

RESULTS

Compound II in CcP. Of all the heme enzymes, C*c*P provides a very convenient framework for examination of ferryl reactivity. But while formation of Compound I in C*c*P is straightforward (because Compound I is a stable intermediate), formation of Compound II with high purity is not. This is in part because the UV-visible spectra of Compounds I and II are very similar^[9] which makes it difficult to differentiate the two. And, it means that the most convenient and commonly used method for Compound II formation – namely by decay of Compound I (*e.g.* ^{[10] [11]}) – cannot be used for C*c*P.

We thus developed an anaerobic procedure for direct formation of Compound II in C*c*P (see Experimental). Under anaerobic conditions, reaction of ferric C*c*P with dithionite led to formation of a stable ferrous species ($\lambda_{max} = 440, 558, 590^{sh}$ nm, Fig. 1A). Further reaction with H₂O₂ yielded a species with wavelength maxima ($\lambda_{max} = 420, 530, 560$ nm, Fig. 1B) similar to those reported for Compound II of C*c*P^[9]. EPR was used to verify Compound II formation; Compound I is EPR-active and Compound II is not. Absorption spectra of EPR samples were recorded prior to flash freezing in EPR tubes, to confirm the correct spectral features (Fig. 2A). The EPR signals characteristic of high-spin ferric C*c*P ($g\perp = 6$ and g|| = 1.99) disappear in the ferrous and Compound II spectra, both of which are EPR-silent, Fig. 2B. No new resonances are observed in the EPR-silent spectrum of Compound II, consistent with the presence of a ferryl heme (S = 1 species).

Single crystal spectrophotometry at 100 K on crystals of C*c*P that had been reduced with dithionite under anaerobic conditions, followed by anaerobic reaction with H_2O_2 (see

Experimental), showed absorption peaks for Compound II ($\lambda_{max} = 530, 560$ nm, Fig. 3A) that reproduce those in solution above. Single crystal EPR spectra, Fig. 3B, also show formation of an EPR-silent species (*i.e* Compound II).

The X-ray free electron laser (XFEL) structure of Compound II of C*c*P, prepared in crystals as above, was obtained at 1.06 Å resolution. Data collection and refinement statistics are given in Table S1. An electron density map in the region of the heme pocket is shown in Fig. 4A. At this resolution it becomes possible to see the peaks in electron density associated with hydrogen atoms, and this difference density is shown in Fig. 5A. Note that although electron density at the positions of hydrogen atoms in Fig. 5A confirms their presence, absence of observed density cannot be taken as unequivocal proof of absence of a hydrogen atom and the imidazole is therefore more likely to be neutral (not protonated). This is in contrast to the neutron structure of Compound I in $CcP^{[12]}$, in which the N ϵ atom of His52 is carrying a proton. This change in protonation is consistent with a role for the distal histidine residue in regulating proton delivery to the ferryl species. Trp51 retains its hydrogen on N ϵ , and the guanidinium group of Arg48 is flat with density for all the hydrogens expected when positively charged, the state observed in the neutron structure of Compound I for all the hydrogens expected when

The Fe-O bond length extracted from this XFEL structure of CcP Compound II is 1.76 Å. The complete models were refined with SHELXL^[13] allowing estimation of individual atomic positional uncertainties (ESU). The ESU of the iron and oxygen positions are 0.004 and 0.02 Å respectively. There are several key points to note when comparing with Compound I. First, the hydrogen bond patterns to the ferryl are the same in CcP Compound I and II (*i.e.* hydrogen bonds to the NE atoms on Arg48 and the NE proton of Trp 51, Figure 5B) and do not allow space for a OH species bonded to the ferryl. These hydrogen bonds to Arg48 and Trp51 appear to be "locked in", as the same hydrogen bonding pattern is observed in the X-ray structure of C*c*P Compound I^[10] and in the neutron structure^[12], Fig. 5B. Since the neutron structure of Compound I in CcP conclusively identifies a Fe^{IV}=O species (from the absence of nuclear density for a OH species), then we therefore interpret this ferryl species in Compound II of CcP as also being unprotonated (*i.e.* a Fe^{IV}=O species). This would be consistent with the fact that the uv-visible spectra of Compounds I and II are indistinguishable. That said, the bond length of 1.76 Å in this CcP Compound II structure is measurably and (within error) longer than that for CcP Compound I (1.63 Å^[10, 12]). Since this bond lengthening does not affect the hydrogen bonding patterns on the distal side, we take this to mean that the bond length of an unprotonated Fe^{IV}=O species can be flexible within a single enzyme (and therefore that factors other than these distal hydrogen bonds affect bond length). We elaborate these ideas in the Discussion.

Compound II in APX. In a set of parallel experiments, single crystals of Compound II in APX were prepared by reaction with *m*-chloroperbenzoic acid, as previously^[14]. Accordingly, an X-ray free electron laser structure of Compound II of APX was also obtained at 1.50 Å resolution (see Table S1). In this structure (unlike CcP above), the resolution is not high enough to see hydrogen atoms. An electron density map of the distal heme region is shown in Fig. 4B. In this structure, the iron-oxygen bond length is 1.87 Å, and the ESU of the iron and oxygen positions are 0.014 and 0.083 Å respectively. This bond length in Compound II in APX is longer than that found in CcP and agrees with previous X-ray^[10] and neutron^[14] structures. While bond lengths are determined from much lower resolution data in neutron experiments, the X-ray^[10], neutron^[14] and XFEL (this work) data are, nevertheless, in

agreement with one another. Positive nuclear density has identified an Fe^{IV}-OH species for Compound II in APX^[14], which is in agreement with the longer bond. The electron density for the side-chain of Arg38 (equivalent to Arg48 in CcP) is weak, occupying two different positions, Fig. 5C. In one location (the "in" position (14)) the N ϵ atom of Arg38 is hydrogen bonded to the ferryl heme, exactly as in CcP above. In the other position ("out"), Arg38 moves away from the ferryl group, and exchanges with a water molecule (Fig. 5C). This movement of the distal Arg residue is not evident in CcP. The functional implications of these differences between APX and CcP are discussed below.

DISCUSSION

A variety of methods have been used to examine the nature of ferryl heme ($Fe^{IV}=O$ versus $Fe^{IV}-OH$). These include resonance Raman and Mossbauer spectroscopies, EXAFS, and X-ray crystallography. Many of these studies have been carried out on peroxidase enzymes, because their ferryl intermediates are well known and are more stable than the corresponding species in other enzymes (such as P450s) which use the same intermediates. It is worth remembering that none of the spectroscopic methods, nor X-ray diffraction (unless at resolutions of *ca.* 1 Å, where the electrons of hydrogen atoms may be seen), can directly identify the locations of hydrogens so the positions of protons are inferred. To add to the technical difficulty, X-ray induced photoreduction, particularly of positively charged centres such as metal ions is acknowledged to occur during crystal structure determination^[15]. Photoreduction can also be an issue in X-ray absorption spectroscopy studies^[16] and resonance Raman studies^[17].

One method where hydrogens (usually as deuterons) are observed directly is in neutron diffraction, and in a neutron experiment photoreduction does not occur because the neutrons are scattered by nuclei and not (as in an X-ray experiment) by electrons. We have previously used neutron diffraction to examine the ferryl species in Compound I of cytochrome *c* peroxidase. The nuclear density maps demonstrate that Compound I in C*c*P is an Fe^{IV}=O species and is not protonated^[12]. These conclusions on Compound I agree with measurements of bond lengths in multi-crystal X-ray^[10, 18] and XFEL^[19] studies on C*c*P, and with kinetic and spectroscopic work on Compound I in two proximal thiolate-ligated heme enzymes (cytochrome P450^[20] and the fungal peroxygenase from *A. aegerita*^[21]). A consensus on Compound I therefore seems to be emerging.

The protonation state of the ferryl heme in Compound II is less well clarified. Positive nuclear density in the neutron crystal structure of Compound II of ascorbate peroxidase $(APX)^{[14]}$ definitely identifies a OH ligand (Fe^{IV}-OH), although recent spectroscopic information is in favour of an unprotonated species^[22]. One philosophy^[11] is that histidine-ligated heme systems are constitutionally unable to form a Fe^{IV}-OH species, because they lack a proximal thiolate (electron donating) ligand which is considered a key requirement. On the other hand, heme enzymes without a thiolate ligand can form Fe^{IV}-OH^[23], so the presence of a thiolate ligand is not essential for Fe^{IV}-OH formation in all cases.

For Compound II, more information is needed to unpick these key biological questions. XFEL provides an alternative approach to both traditional X-ray crystallography and to neutron crystallography techniques, in the sense that structures can be generated on femtosecond timecales that avoid X-ray induced photoreduction or radiation damage. The XFEL structure of Compound II of C*c*P, resolved to 1.06 Å, shows a Fe-O bond length of 1.76 Å. This bond length is longer than that obtained using a multi-crystal X-ray method for Compound I of C*c*P (1.63 Å, determined at 1.67 Å resolution and with an ESU of the iron

and oxygen atom positions of 0.017 and 0.066 Å respectively^[10]). The corresponding XFEL structure of Compound II in APX, resolved at 1.50 Å, shows a Fe-O distance of 1.87 Å which is almost identical to that obtained from multi-crystal X-ray (1.84 Å^[10]) and neutron structures (1.88 Å^[14], as shown in Fig. S3).

Comparison with other ferryl species

Empirically-determined distances for Fe-O bond lengths are quite reasonably often used as a binary determinant of bond order (single or double bond) and, by implication, of protonation state in ferryl complexes. But the comparison of the closely related CcP and APX enzymes above and the analysis below indicates that the situation might be considerably more complicated. Comparison of CcP and APX shows evident flexibility (or certainly variability) in the bond lengths of ferryl species. The most reliable bond lengths for Compound I in proteins have typically been within a range of ca 1.63 - 1.73 Å (Table S2) and are assigned as arising from Fe^{IV}=O species. For Fe^{IV}-OH species, the bond is expected to be longer than for Fe^{IV}=O, but by how much? The Fe^{IV}=O bond length itself can vary, as we show above for Compounds I and II in CcP and also in Table S1, so there may be movement in these protein bond lengths for Fe^{IV}=O, Fe^{IV}=O, Fe^{IV}-OH and even Fe^{III}-OH species, making them hard to differentiate by virtue of bond length alone.

There is evidence to support such flexibility in other enzymes. Consider for example the Fe^{IV}-OH bond length for chloroperoxidase Compound II (1.82 Å^[24]) which is very close to the Fe^{III}-OH bond length in myoglobin (1.86 Å^[25]). Consider also that in Compound II of *H. pylori* catalase^[23a] the Fe-O bond length (1.78 Å) has been interpreted^[23a] as a Fe^{IV}-OH species (in agreement with *P. mirabilis* catalase^[23b]), but is arguably is within range of an unprotonated (Fe^{IV}=O) species (*e.g.* 1.73 Å^[18]). That the bond lengths for some Compound II intermediates are in a range that overlap with Fe^{III}-OH, and that bond lengths for Fe^{IV}=O and Fe^{IV}-OH species can be closely merged together in different proteins, blurs the boundaries between individual species. We note also a recent XFEL analysis^[26] of a stable Compound I species in a dye-decolorising peroxidase (DyP), which shows the expected short Fe-O bond length in one monomer of the crystal (1.65 Å), but much longer bonds (1.70 – 1.89 Å) in five others of the asymmetric unit at both room temperature (from XFEL data) and at 100 K (from synchrotron data).

An examination of structures of inorganic ferryl complexes further elaborates the above analysis. A range of bond lengths is observed for genuine $Fe^{IV}=O$ species (1.62 – 1.70 Å, Fig. 6B); these are notably shorter than the equivalent Fe^{III} –OH species, Fig. 6A. The range of Fe-O bond lengths for Compound I protein species (1.63 – 1.73 Å) is wider, but in reasonable agreement of those for the inorganic complexes (compare Fig. 6B,C). Regardless of whether they are assigned as $Fe^{IV}=O$ or Fe^{IV} -OH species, the bond lengths for Compounds II are all longer (1.76 Å– 1.88 Å, Fig. 6D). The only structure for an inorganic Fe^{IV} -OH species reports a similar bond length of 1.86 Å^[27], highlighted in Fig. 6B, but the both the inorganic and protein Fe^{IV} -OH species are in a region that overlaps with the numerous Fe^{III} -OH structures, Fig. 6A.

Functional implications

Taking all of this information together, while considering at the same time the enzymatic requirements to do with the O-O bond cleavage event, it appears that there is a range of bond lengths that any particular species (Fe^{IV}=O or Fe^{IV}-OH) might populate. Flexing of the bond and the bonding parameters might better reflect the range of dynamic motions that occur

around the ferryl heme in different heme enzymes during catalytic turnover. This could be moderated by variables such as axial ligand, local charge, temperature, secondary coordination sphere and in particular hydrogen bonding^[28] as discussed below.

The data from the two XFEL structures of Compound II highlights differences in hydrogen bonding in the active site of these two closely related heme enzymes. In Compound II of APX, the distal Arg38 residue is mobile and is observed in two conformations in the structure. This is not observed in CcP. Movement of Arg38 changes the hydrogen bonding patterns in the active site, as shown in Fig. 5C. Arg38 is involved in proton delivery from the substrate (ascorbate) to the heme group during catalysis^[29]. And, neutron crystallography^[30] supports a role for Arg38 in proton delivery because Arg 38 is neutral (having lost a proton in the complex) in the APX-ascorbate complex. In one of the two locations for Arg38 (the "out" position, Fig. 5C (left)), there is a water molecule hydrogen bonded to the ferryl oxygen. In the other "in" position (Fig. 5C (right)), Arg38 hydrogen bonds to the ferryl oxygen in the same way as in CcP (Figure 5B); in this conformation Arg38 would need to be a hydrogen acceptor to a proton on the ferryl oxygen, and this can only be achieved if Arg38 is in the neutral state (as seen in^[30]). This highly dynamic hydrogen bonding arrangement in APX is presumably linked to the functional need for proton transfer from the substrate (ascorbate) and mediated by movement of Arg38 - it involves two proton donors (water and Arg38) in two conformations. This could account for the longer Fe-O bond in Compound II of APX compared to CcP, and would provide a mechanism to facilitate movement of protons in an out of the active site. Hydrogen bonding to the distal histidine residue (or in other words whether the distal histidine is protonated or not) might also be important in regulating the bonding parameters^[31]. There is strong evidence from this study and our previous work for different protonation states of the distal histidine^[12, 14, 30], which will change the hydrogen bonding patterns. We note also that pH-dependent changes in resonance Raman stretching frequencies for Compound II of both horseradish peroxidase^[32] and myoglobin^[25] are generally considered to arise from changes in hydrogen bonding to the ferryl.

By comparison, as we have shown above, no such flexibility in hydrogen bonding to the distal Arg is observed in CcP, as the active site hydrogen bond structure is "locked" in a fixed arrangement that does not change between Compounds I and II. That the electron transfer delivery pathway between ascorbate and the ferryl heme in APX (through Arg38 and the heme propionate^[33]) is not replicated in CcP would be consistent with the different patterns of hydrogen bonding that we observe. In CcP, the electrons are delivered from cytochrome c through the proximal side^[34], and so shuttling of protons from a substrate (at the heme edge) to the ferryl, mediated by the distal Arg, and changes in hydrogen bonding, are not a requiste part of the mechanism.

These results demonstrate not only the precise fine-tuning that can exist within structurally almost identical heme active sites, but the ways in which this is connected to functional differences to do with substrate specificity. This information will feed into *de novo* design of new catalysts, aimed at mimicking heme protein reactivity and selectivity.

ACKNOWLEDGMENTS

This work was supported by BBSRC grants BB/N015940/1 and BB/S020586/1 and travel grants from Diamond Light Source to P.C.E.M. and E.L.R. EPR experiments were carried out in the EPSRC National EPR Research Facility & Service (NS/A000055/1). We acknowledge access to SACLA (experiments (2018A8009, 2019B8009, 2020A8030) and JSPS for support (grant JP20H05452 to H.S. and JP19H05783 to M.Y.).

KEYWORDS

Heme proteins, heme, peroxidase.

REFERENCES

- a) J. T. Groves, *J Inorg Biochem* 2006, *100*, 434-447; b) P. C. E. Moody, E. L. Raven, *Acc Chem Res* 2018, *51*, 427-435.
- [2] a) D. Keilin, T. Mann, Proc. Roy. Soc. (London) 1937, 122B, 119-133; b) H. Theorell, Enzymologia 1941, 10, 250-252.
- [3] a) D. Keilin, E. F. Hartree, *Biochem J* 1951, 49, 88-104; b) P. George, *Nature* 1952, 169, 612-613; c) P. George, *J Biol Chem* 1953, 201, 427-434.
- [4] a) J. T. Groves, *Nature chemistry* 2014, *6*, 89-91; b) S. G. Sligar, *Science* 2010, *330*, 924-925;
 c) K. D. Karlin, *Nature* 2010, *463*, 168-169.
- [5] R. K. Behan, M. T. Green, *J Inorg Biochem* **2006**, *100*, 448-459.
- [6] a) J. Yano, J. Kern, K. D. Irrgang, M. J. Latimer, U. Bergmann, P. Glatzel, Y. Pushkar, J. Biesiadka, B. Loll, K. Sauer, J. Messinger, A. Zouni, V. K. Yachandra, *Proc Natl Acad Sci U S A* 2005, *102*, 12047-12052; b) T. Beitlich, K. Kuhnel, C. Schulze-Briese, R. L. Shoeman, I. Schlichting, *Journal of synchrotron radiation* 2007, *14*, 11-23; c) A. Ebrahim, T. Moreno-Chicano, M. V. Appleby, A. K. Chaplin, J. H. Beale, D. A. Sherrell, H. M. E. Duyvesteyn, S. Owada, K. Tono, H. Sugimoto, R. W. Strange, J. A. R. Worrall, D. Axford, R. L. Owen, M. A. Hough, *IUCrJ* 2019, *6*, 543-551.
- [7] T. L. Poulos, *Chemical reviews* **2014**, *114*, 3919-3962.
- [8] a) I. Inoue, Y. Inubushi, T. Sato, K. Tono, T. Katayama, T. Kameshima, K. Ogawa, T. Togashi, S. Owada, Y. Amemiya, T. Tanaka, T. Hara, M. Yabashi, *Proc Natl Acad Sci U S A* 2016, *113*, 1492-1497; b) K. Hirata, K. Shinzawa-Itoh, N. Yano, S. Takemura, K. Kato, M. Hatanaka, K. Muramoto, T. Kawahara, T. Tsukihara, E. Yamashita, K. Tono, G. Ueno, T. Hikima, H. Murakami, Y. Inubushi, M. Yabashi, T. Ishikawa, M. Yamamoto, T. Ogura, H. Sugimoto, J. R. Shen, S. Yoshikawa, H. Ago, *Nature methods* 2014, *11*, 734-736; c) R. Neutze, R. Wouts, D. van der Spoel, E. Weckert, J. Hajdu, *Nature* 2000, *406*, 752-757.
- [9] A. E. Pond, G. S. Bruce, A. M. English, M. Sono, J. H. Dawson, *Inorg Chim Acta* 1998, 276, 250-255.
- [10] A. Gumiero, C. L. Metcalfe, A. R. Pearson, E. L. Raven, P. C. Moody, J. Biol. Chem. 2011, 286, 1260-1268.
- [11] T. H. Yosca, J. Rittle, C. M. Krest, E. L. Onderko, A. Silakov, J. C. Calixto, R. K. Behan, M. T. Green, *Science* 2013, 342, 825-829.
- [12] C. M. Casadei, A. Gumiero, C. L. Metcalfe, E. J. Murphy, J. Basran, M. G. Concilio, S. C. Teixeira, T. E. Schrader, A. J. Fielding, A. Ostermann, M. P. Blakeley, E. L. Raven, P. C. Moody, *Science* 2014, 345, 193-197.
- [13] G. M. Sheldrick, Acta Crystallogr C Struct Chem 2015, 71, 3-8.
- [14] H. Kwon, J. Basran, C. M. Casadei, A. J. Fielding, T. E. Schrader, A. Ostermann, J. M. Devos, P. Aller, M. P. Blakeley, P. C. E. Moody, E. L. Raven, *Nat Commun* 2016, 7, DOI: 10.1038/ncomms13445.
- [15] a) E. de la Mora, N. Coquelle, C. S. Bury, M. Rosenthal, J. M. Holton, I. Carmichael, E. F. Garman, M. Burghammer, J. P. Colletier, M. Weik, *Proc Natl Acad Sci U S A* 2020, *117*, 4142-4151; b) E. F. Garman, M. Weik, *Methods Mol Biol* 2017, *1607*, 467-489; c) H. Kwon, O. Smith, E. L. Raven, P. C. Moody, *Acta Crystallogr D Struct Biol* 2017, *73*, 141-147.
- [16] G. N. George, I. J. Pickering, M. J. Pushie, K. Nienaber, M. J. Hackett, I. Ascone, B. Hedman, K. O. Hodgson, J. B. Aitken, A. Levina, C. Glover, P. A. Lay, *Journal of synchrotron radiation* 2012, 19, 875-886.
- [17] J. Terner, V. Palaniappan, A. Gold, R. Weiss, M. M. Fitzgerald, A. M. Sullivan, C. M. Hosten, *J Inorg Biochem* **2006**, *100*, 480-501.
- [18] Y. T. Meharenna, T. Doukov, H. Li, S. M. Soltis, T. L. Poulos, *Biochemistry* **2010**, *49*, 2984-2986.
- [19] G. Chreifi, E. L. Baxter, T. Doukov, A. E. Cohen, S. E. McPhillips, J. Song, Y. T. Meharenna, S. M. Soltis, T. L. Poulos, *Proc Natl Acad Sci U S A* 2016, *113*, 1226-1231.

- [20] J. Rittle, M. T. Green, *Science* **2010**, *330*, 933-937.
- [21] X. Wang, S. Peter, M. Kinne, M. Hofrichter, J. T. Groves, J Am Chem Soc 2012, 134, 12897-12900.
- [22] A. P. Ledray, C. M. Krest, T. H. Yosca, K. Mittra, M. T. Green, J Am Chem Soc 2020.
- [23] a) T. H. Yosca, M. C. Langston, C. M. Krest, E. L. Onderko, T. L. Grove, J. Livada, M. T. Green, *J Am Chem Soc* 2016, *138*, 16016-16023; b) O. Horner, J. M. Mouesca, P. L. Solari, M. Orio, J. L. Oddou, P. Bonville, H. M. Jouve, *J Biol Inorg Chem* 2007, *12*, 509-525.
- [24] K. L. Stone, R. K. Behan, M. T. Green, Proc Natl Acad Sci USA 2006, 103, 12307-12310.
- [25] T. H. Yosca, R. K. Behan, C. M. Krest, E. L. Onderko, M. C. Langston, M. T. Green, *J Am Chem Soc* 2014, *136*, 9124-9131.
- [26] M. Lucic, D. A. Svistunenko, M. T. Wilson, A. K. Chaplin, B. Davy, A. Ebrahim, D. Axford, T. Tosha, H. Sugimoto, S. Owada, F. S. N. Dworkowski, I. Tews, R. L. Owen, M. A. Hough, J. A. R. Worrall, *Angew Chem Int Ed Engl* 2020, 59, 21656-21662.
- [27] J. P. T. Zaragoza, T. H. Yosca, M. A. Siegler, P. Moenne-Loccoz, M. T. Green, D. P. Goldberg, J Am Chem Soc 2017, 139, 13640-13643.
- [28] a) V. F. Oswald, J. L. Lee, S. Biswas, A. C. Weitz, K. Mittra, R. Fan, J. Li, J. Zhao, M. Y. Hu, E. E. Alp, E. L. Bominaar, Y. Guo, M. T. Green, M. P. Hendrich, A. S. Borovik, *J Am Chem Soc* 2020, *142*, 11804-11817; b) Z. Gordon, M. J. Drummond, E. M. Matson, J. A. Bogart, E. J. Schelter, R. L. Lord, A. R. Fout, *Inorg Chem* 2017, *56*, 4852-4863.
- [29] I. Efimov, S. K. Badyal, C. L. Metcalfe, I. Macdonald, A. Gumiero, E. L. Raven, P. C. Moody, J Am Chem Soc 2011, 133, 15376-15383.
- [30] H. Kwon, J. Basran, J. M. Devos, R. Suardiaz, M. W. van der Kamp, A. J. Mulholland, T. E. Schrader, A. Ostermann, M. P. Blakeley, P. C. E. Moody, E. L. Raven, *Proc Natl Acad Sci U S A* 2020, *117*, 6484-6490.
- [31] K. Nilsson, H. P. Hersleth, T. H. Rod, K. K. Andersson, U. Ryde, *Biophys J* 2004, *87*, 3437-3447.
- [32] A. J. Sitter, C. M. Reczek, J. Terner, J Biol Chem 1985, 260, 7515-7522.
- [33] K. H. Sharp, M. Mewies, P. C. Moody, E. L. Raven, *Nature structural biology* 2003, 10, 303-307.
- [34] H. Pelletier, J. Kraut, *Science* **1992**, *258*, 1748-1755.
- [35] a) C. E. MacBeth, A. P. Golombek, V. G. Young, Jr., C. Yang, K. Kuczera, M. P. Hendrich, A. S. Borovik, *Science* 2000, 289, 938-941; b) C. L. Ford, Y. J. Park, E. M. Matson, Z. Gordon, A. R. Fout, *Science* 2016, 354, 741-743; c) E. M. Matson, Y. J. Park, A. R. Fout, *J Am Chem Soc* 2014, 136, 17398-17401.

FIGURE LEGENDS

Figure 1. Formation of Compound II in CcP monitored by stopped-flow. (A) Formation of ferrous CcP – Ferric CcP (6 µM) was mixed with 2-3 equivalents of dithionite and spectra monitored over 10 s. The dashed line is the first species observed after mixing and represents the ferric enzyme, and the solid line represents the ferrous spectrum which was completely formed within 10s of the mixing event. Absorbance values in the visible region have been multiplied by a factor of three. Conditions: 10 mM potassium phosphate, 150 mM KCl pH 6.5, 25.0 °C. This ferrous species was stable for at least 15 minutes at room temperature, after which time it decayed back to ferric. (B) Formation of CcP Compound II – In a sequential mixing experiment ferric CcP (6 μ M) was premixed with a stoichiometric amount of dithionite for 10 s (to enable complete formation of ferrous CcP) followed by mixing with H₂O₂ (5 equivalents) and spectral changes monitored over 10 s. The dashed line is the first species observed after mixing and represents the ferrous species (at t = 1 ms); this spectrum $(\lambda_{max} = 439, 558, 590^{sh} \text{ nm})$ is similar to the spectrum of the ferrous enzyme formed in the single mix experiments in (A). The solid line after reaction with H₂O₂ is assigned as a Compound II species ($\lambda_{max} = 420, 530, 560 \text{ nm}$). Over longer timescales (~ 500 s), this Compound II species was observed to decay slowly ($k_{obs} \approx 0.004 \text{ s}^{-1}$) back to a ferric-like species (Fig. S1).

Figure 2. Formation of Compound II in C*c*P monitored by EPR. (A) Absorption spectra of ferric, ferrous and Compound II forms of C*c*P used for EPR analysis – Ferric C*c*P (250 μ M, dotted line) was reacted with 5-10 equivalents of dithionite to produce ferrous C*c*P (dashed line); Compound II (black solid line) was prepared by reaction of ferrous protein with 10 equivalents of H₂O₂. All spectra were recorded immediately after mixing and prior to flash freezing. Absorbance values in the visible region have been multiplied by a factor of three. Conditions: 10 mM potassium phosphate, 150 mM KCl pH 6.5, 25.0 °C. (B) EPR spectra – 9 GHz EPR spectra of the corresponding solutions from the experiments in (A) of the ferric (top spectrum), ferrous (middle spectrum) and Compound II (bottom spectrum) derivatives of C*c*P prepared by reaction of ferrous C*c*P with 10-equivalents of H₂O₂ and flash frozen immediately after mixing (see Experimental).

Figure 3. Formation of Compound II of CcP in crystals. (A) Single crystal UV-visible spectra (100 K) of crystals of formed by reaction with dithionite (to give ferrous CcP, solid line), followed by reaction with 0.2 mM H₂O₂ (to give Compound II, dashed line). (B) 9 GHz EPR spectra of single crystals of CcP. (i) Ferric CcP. (ii) Compound I formed by reaction of a ferric crystal with 0.2 mM H₂O₂. (iii) After storage of the crystal in (ii) for 20 days in liquid nitrogen; (iv) Compound II formed by reaction with dithionite and H₂O₂ as in (A). (v) After storage of the sample in (iv) for 20 days in liquid nitrogen; (vi) Background. **Figure 4.** XFEL crystal structures of Compound II. (A) CcP Compound II – Electron density of CcP Compound II is shown in blue (contoured at 2.0 σ). The O atom is positioned at 1.76 Å from the heme iron. Oxygen atoms of water molecules are shown in light blue, and the ferryl oxygen is shown in red (to differentiate it from water). (B) APX Compound II – Electron density calculated by omitting Arg 38 is shown in green (contoured at 3 σ). Note the weak density beyond the C δ of the side chain for Arg 38 (shown at 1.2 σ). Atoms of Arg 38 are shown in grey where the atomic positions are unclearly defined. The ferryl O atom is

positioned at 1.87 Å from the heme iron. Oxygen atoms of water molecules are shown in light blue, and the ferryl oxygen is shown in red, as for (A).

Figure 5. Hydrogen bonding in the active site. (A) Electron density of C*c*P Compound II is shown in blue (contoured at 2.0 σ). The difference density calculated by omitting hydrogens are shown in green (contoured at 3 σ). The O atom is positioned at 1.76 Å from the heme iron. Water is shown in light blue color. (B) Hydrogen bonding patterns for Compound II in C*c*P. (C) Hydrogen bonding patterns for Compound II in APX showing Arg38 in two different locations - the "out" (left, as in Figure 4B above) and "in" (right) positions. Waters are shown in light blue, and swap interchangeably as Arg38 moves between the two locations. Note that in the 'out' position, Arg38 is hydrogen bonded to the water molecule through the N η , and not as previously^[14] through the adjacent N ϵ . The ferryl oxygen is shown in red and hydrogen bonds are in dotted lines in all figures.

Figure 6. Comparison of Fe-O bond lengths obtained for various ferric (A) and ferryl (B) inorganic structures in the Cambridge Structure Database, alongside those for Compound I and Compound II protein structures (C, D). Photoreduction is not a complicating factor in small molecule crystal structures. (A) Plot showing Fe-O bond lengths for complexes of iron in the ferric oxidation state in the Cambridge Structure Database. The plot shows only ferric structures with hydroxide (OH, highlighted in red circles) or water (H₂O, black) as a ligand to the iron. Not shown in this plot, are structures for a Fe^{III}=O species (Fe-O = 1.81 Å ^[35]). The majority (all but three) of the Fe^{III}-OH structures in the CSD lie in the range 1.8 – 1.9 Å. (B) The equivalent plot for complexes of iron in the ferryl oxidation state, in the Cambridge Structure which is assigned as Fe^{IV}-OH (red circle ^[27]). Exact bonds lengths for each of the individual Fe^{IV} species are given in the SI. (C) Fe-O bond distances obtained from crystal

structures of Compound I (see also Table S2). (D) The same as (C), but for Compound II (see also Table S2).

Figure 1 Kwon et al







Figure 3 Kwon et al











Figure 6 Kwon et al



GRAPHICAL ABSTRACT

Enzymatic fine-tuning of heme reactivity. Free-electron laser crystal structures of two different heme-containing peroxidases – cytochrome *c* peroxidase and ascorbate peroxidase – show differences in the nature of the ferryl species. Precise enzymatic fine-tuning within structurally similar heme active sites is implicated.



Cytochrome *c* Peroxidase

Ascorbate Peroxidase